Non-Invasive Prenatal Testing Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Prenatal Testing Market 

5.1. COVID-19 Landscape: Non-Invasive Prenatal Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Prenatal Testing Market, By Component

8.1. Non-Invasive Prenatal Testing Market, by Component, 2024-2034

8.1.1 Instruments

8.1.1.1. Market Revenue and Forecast (2023-2034)

8.1.2. Kits and Reagents

8.1.2.1. Market Revenue and Forecast (2023-2034)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2023-2034)

Chapter 9. Global Non-Invasive Prenatal Testing Market, By Application

9.1. Non-Invasive Prenatal Testing Market, by Application, 2024-2034

9.1.1. Down Syndrome (trisomy 21)

9.1.1.1. Market Revenue and Forecast (2023-2034)

9.1.2. Edwards Syndrome (trisomy 18)

9.1.2.1. Market Revenue and Forecast (2023-2034)

9.1.3. Patau Syndrome (trisomy 13)

9.1.3.1. Market Revenue and Forecast (2023-2034)

9.1.4. Turner Syndrome

9.1.4.1. Market Revenue and Forecast (2023-2034)

9.1.5. Other Applications

9.1.5.1. Market Revenue and Forecast (2023-2034)

Chapter 10. Global Non-Invasive Prenatal Testing Market, By End User 

10.1. Non-Invasive Prenatal Testing Market, by End User, 2024-2034

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2023-2034)

10.1.2. Diagnostic Labs

10.1.2.1. Market Revenue and Forecast (2023-2034)

Chapter 11. Global Non-Invasive Prenatal Testing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Component (2023-2034)

11.1.2. Market Revenue and Forecast, by Application (2023-2034)

11.1.3. Market Revenue and Forecast, by End User (2023-2034)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.1.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.1.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.1.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.1.5.3. Market Revenue and Forecast, by End User (2023-2034)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Component (2023-2034)

11.2.2. Market Revenue and Forecast, by Application (2023-2034)

11.2.3. Market Revenue and Forecast, by End User (2023-2034)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.2.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.2.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.2.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.2.5.3. Market Revenue and Forecast, by End User (2023-2034)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Component (2023-2034)

11.2.6.2. Market Revenue and Forecast, by Application (2023-2034)

11.2.6.3. Market Revenue and Forecast, by End User (2023-2034)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Component (2023-2034)

11.2.7.2. Market Revenue and Forecast, by Application (2023-2034)

11.2.7.3. Market Revenue and Forecast, by End User (2023-2034)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Component (2023-2034)

11.3.2. Market Revenue and Forecast, by Application (2023-2034)

11.3.3. Market Revenue and Forecast, by End User (2023-2034)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.3.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.3.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.3.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.3.5.3. Market Revenue and Forecast, by End User (2023-2034)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Component (2023-2034)

11.3.6.2. Market Revenue and Forecast, by Application (2023-2034)

11.3.6.3. Market Revenue and Forecast, by End User (2023-2034)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Component (2023-2034)

11.3.7.2. Market Revenue and Forecast, by Application (2023-2034)

11.3.7.3. Market Revenue and Forecast, by End User (2023-2034)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.4.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.4.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.4.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.4.5.3. Market Revenue and Forecast, by End User (2023-2034)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Component (2023-2034)

11.4.6.2. Market Revenue and Forecast, by Application (2023-2034)

11.4.6.3. Market Revenue and Forecast, by End User (2023-2034)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Component (2023-2034)

11.4.7.2. Market Revenue and Forecast, by Application (2023-2034)

11.4.7.3. Market Revenue and Forecast, by End User (2023-2034)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.5.3. Market Revenue and Forecast, by End User (2023-2034)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Component (2023-2034)

11.5.4.2. Market Revenue and Forecast, by Application (2023-2034)

11.5.4.3. Market Revenue and Forecast, by End User (2023-2034)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Component (2023-2034)

11.5.5.2. Market Revenue and Forecast, by Application (2023-2034)

11.5.5.3. Market Revenue and Forecast, by End User (2023-2034)

Chapter 12. Company Profiles

12.1. Genesis Genetics (CooperSurgical, Inc.)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Natera, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Centogene N.V.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc. (Verinata Health, Inc.)

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eurofins LifeCodexx GmbH

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. MedGenome Labs Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Myriad Women’s Health, Inc. (Counsyl, Inc.)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Progenity, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Qiagen

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms